Distributions and prognostic effects of ABO/Rh blood groups in patients with HER2/neu positive gastric and gastroesophageal junction cancer
Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics..
BACKGROUND: The aim of study was to look at ABO/Rh blood types frequency and prognostic significance in patients with HER2/neu positive gastric cancer.
METHODS: The study was designed retrospectively. Clinicopathological characteristics, treatment approaches, and the ABO/Rh blood groups features were noted. The ABO/Rh blood types for patients and healthy donors were compared by the Chi-square method.
RESULTS: The average age was 61 years. The average survival time was 17.9 months (13.2-22.5). ABO blood types frequencies were not similar between patients (25.9% O, 6.3% AB, 57.1% A, and 10.7% B) and control group (34.9% O, 7.9% AB, 41.9% A, and 15.3% B) (P = 0.01). Patients and controls had the same Rh factor distribution (P = 0.07).
CONCLUSIONS: We showed that A blood group frequency was increased in patients with HER2/neu receptor-positive gastric cancer than in a healthy population. Also, we detected that the frequency of O blood type was decreased. ABO/Rh blood types were not linked with prognosis for overall survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of cancer research and therapeutics - 19(2023), Suppl 2 vom: 01. Jan., Seite S747-S751 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dogan, Izzet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ABO Blood-Group System |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4103/jcrt.jcrt_1520_22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368740595 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368740595 | ||
| 003 | DE-627 | ||
| 005 | 20240229144655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/jcrt.jcrt_1520_22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM368740595 | ||
| 035 | |a (NLM)38384050 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dogan, Izzet |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Distributions and prognostic effects of ABO/Rh blood groups in patients with HER2/neu positive gastric and gastroesophageal junction cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics. | ||
| 520 | |a BACKGROUND: The aim of study was to look at ABO/Rh blood types frequency and prognostic significance in patients with HER2/neu positive gastric cancer | ||
| 520 | |a METHODS: The study was designed retrospectively. Clinicopathological characteristics, treatment approaches, and the ABO/Rh blood groups features were noted. The ABO/Rh blood types for patients and healthy donors were compared by the Chi-square method | ||
| 520 | |a RESULTS: The average age was 61 years. The average survival time was 17.9 months (13.2-22.5). ABO blood types frequencies were not similar between patients (25.9% O, 6.3% AB, 57.1% A, and 10.7% B) and control group (34.9% O, 7.9% AB, 41.9% A, and 15.3% B) (P = 0.01). Patients and controls had the same Rh factor distribution (P = 0.07) | ||
| 520 | |a CONCLUSIONS: We showed that A blood group frequency was increased in patients with HER2/neu receptor-positive gastric cancer than in a healthy population. Also, we detected that the frequency of O blood type was decreased. ABO/Rh blood types were not linked with prognosis for overall survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Rh-Hr Blood-Group System |2 NLM | |
| 650 | 7 | |a ABO Blood-Group System |2 NLM | |
| 700 | 1 | |a Gurbuz, Mustafa |e verfasserin |4 aut | |
| 700 | 1 | |a Aydin, Esra |e verfasserin |4 aut | |
| 700 | 1 | |a Karabulut, Senem |e verfasserin |4 aut | |
| 700 | 1 | |a Tastekin, Didem |e verfasserin |4 aut | |
| 700 | 1 | |a Utkan, Gungor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and therapeutics |d 2005 |g 19(2023), Suppl 2 vom: 01. Jan., Seite S747-S751 |w (DE-627)NLM174976801 |x 1998-4138 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:Suppl 2 |g day:01 |g month:01 |g pages:S747-S751 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/jcrt.jcrt_1520_22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e Suppl 2 |b 01 |c 01 |h S747-S751 | ||